Callan Family Office LLC Purchases 4,135 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Callan Family Office LLC raised its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 217.1% during the 2nd quarter, HoldingsChannel reports. The fund owned 6,040 shares of the biopharmaceutical company’s stock after buying an additional 4,135 shares during the quarter. Callan Family Office LLC’s holdings in Regeneron Pharmaceuticals were worth $3,171,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. E Fund Management Hong Kong Co. Ltd. lifted its stake in Regeneron Pharmaceuticals by 344.4% in the 1st quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 31 shares in the last quarter. Activest Wealth Management lifted its stake in Regeneron Pharmaceuticals by 110.5% in the 1st quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 21 shares in the last quarter. Costello Asset Management INC bought a new stake in Regeneron Pharmaceuticals in the 1st quarter valued at approximately $27,000. Saudi Central Bank bought a new stake in shares of Regeneron Pharmaceuticals during the 1st quarter worth approximately $27,000. Finally, Colonial Trust Advisors bought a new stake in shares of Regeneron Pharmaceuticals during the 1st quarter worth approximately $32,000. Institutional investors own 83.31% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the company. Jefferies Financial Group upped their price objective on Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the stock a “buy” rating in a research note on Wednesday, August 27th. Argus cut Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, June 30th. Truist Financial dropped their price objective on Regeneron Pharmaceuticals from $940.00 to $812.00 and set a “buy” rating on the stock in a research note on Monday, August 11th. Redburn Atlantic upgraded Regeneron Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, August 14th. Finally, Royal Bank Of Canada upped their price objective on Regeneron Pharmaceuticals from $688.00 to $695.00 and gave the stock a “sector perform” rating in a research note on Monday, August 4th. Three equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $817.46.

Regeneron Pharmaceuticals Stock Down 0.9%

REGN stock opened at $564.63 on Friday. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.60 and a quick ratio of 3.72. The stock has a market capitalization of $59.85 billion, a price-to-earnings ratio of 14.23, a PEG ratio of 1.82 and a beta of 0.31. The business’s fifty day moving average price is $573.95 and its two-hundred day moving average price is $565.04. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $476.49 and a fifty-two week high of $1,024.36.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, topping the consensus estimate of $8.43 by $4.46. The firm had revenue of $3.68 billion for the quarter, compared to analysts’ expectations of $3.30 billion. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The company’s quarterly revenue was up 3.6% compared to the same quarter last year. During the same quarter last year, the business earned $11.56 EPS. On average, equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th were given a dividend of $0.88 per share. The ex-dividend date was Monday, August 18th. This represents a $3.52 annualized dividend and a yield of 0.6%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 8.87%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.